Uncategorized
AbbVie receives positive opinion in Europe for Humira as treatment for noninfectious uveitis
AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for Humira as a treatment for noninfectious uveitis, according to a company press release. If approved by the European Commission, Humira (adalimumab) “would be the first biologic treatment option offered in the European Union for certain patients with noninfectious intermediate, posterior and panuveitis,” the release said.